Exagen Inc. XGN R&D credit carryforward
R&D credit carryforward at other companies
Other financials
Where this comes from
Reported directly by Exagen Inc. in its filing.
Tagged under the XBRL concept us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch.
The official record: Exagen Inc.’s 10-K, filed March 10, 2026, on SEC EDGAR. View the filing →
Ask your AI about Exagen Inc.'s r&d credit carryforward.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Exagen Inc.'s r&d credit carryforward?
- Exagen Inc. (XGN) reported r&d credit carryforward of $2.36M in Q4 2025.
- How has Exagen Inc.'s r&d credit carryforward changed year-over-year?
- Exagen Inc.'s r&d credit carryforward decreased by 0.0% year-over-year, from $2.36M to $2.36M.
- What is the long-term trend for Exagen Inc.'s r&d credit carryforward?
- Over 5 years (2020 to 2025), Exagen Inc.'s r&d credit carryforward has grown at a 30.3% compound annual growth rate (CAGR), from $629K to $2.36M.
- What does r&d credit carryforward mean?
- The accumulated value of tax credits generated from research and development activities that can be applied to offset future tax liabilities. This asset represents a potential future cash flow benefit by reducing the company's effective tax burden. It highlights the company's historical investment in innovation and its ability to utilize tax incentives.